Showing results (41-50 of 122) with videos related to

Sort By:
Pageof 13
Expert Opinion on Drug Delivery|April 13, 2026
Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myelomaEnrique M Ocio, Gurdeep Parmar, María-Victoria Mateos, et al.
Blood|May 31, 2014
Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myelomaBruno Paiva, Mauricio Chandia, Maria-Belen Vidriales, et al.
Transplantation and Cellular Therapy|November 27, 2022
Feasibility of a Hospital-at-Home Program for Autologous Hematopoietic Stem Cell TransplantationSoledad González-Barrera, Guillermo Martín-Sánchez, Juan José Parra-Jordán, et al.
Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2017
Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple MyelomaElizabeta A Rojas, Luis Antonio Corchete, Laura San-Segundo, et al.
Haematologica|December 3, 2009
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaEnrique M Ocio, David Vilanova, Peter Atadja, et al.
Leukemia|May 24, 2020
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysisMeletios A Dimopoulos, Xavier Leleu, Philippe Moreau, et al.
Haematologica|August 30, 2023
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa studyEnrique M Ocio, Yvonne A Efebera, Roman Hájek, et al.
Cancers|September 29, 2020
Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple MyelomaTeresa Paíno, Lorena González-Méndez, Laura San-Segundo, et al.
Cancer Medicine|September 21, 2022
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myelomaMaría Victoria Mateos, Felipe Prosper, Jesús Martin Sánchez, et al.
Pageof 13